Senhwa Biosciences Inc (生華科) yesterday said it has partnered with the US National Institutes of Health (NIH) to evaluate the efficacy of a new drug, dubbed Silmitasertib, for treatment of COVID-19.
The drug, developed by Senhwa Biosciences to treat cancers, such as bile duct cancer, medulloblastoma and pediatric brain tumor, showed promise in human tests to curb the ribonucleic acid (RNA) virus from proliferating.
“With the attribute, the drug is expected to help combat the novel coronavirus. We have not tested the drug on patients with COVID-19 in Taiwan, but the US NIH, looking forward to the drug’s efficacy, will run some trials in the US,” Senhwa Biosciences CEO Soong Tai-sen (宋台生) said by telephone.
The company would offer the drug for free to the US agency during the tests, but it is difficult to forecast when the trials would be completed, Soong said.
The New Taipei City-based firm has no intention of running human trials for COVID-19 treatment in Taiwan, as it has put all of its resources into its clinical trials on cancer treatment, but it is willing to partner with other companies and provide its drugs for free, Soong said.
The University of California San Francisco’s Quantitative Biosciences Institute last month identified 69 drugs or experimental compounds that might be effective in treating COVID-19, including the Silmitasertib, Soong said.
Silmitasertib could promote the formation of street granules by disrupting casein kinase 2, a protein kinase that performs diverse functions related to cell survival, thus preventing viruses from gaining ingredients such as nucleic acids to create a new virus, Soong said.
“Silmitasertib offers two advantages. First, its safety has been proven during our previous tests on about 300 people for cancer treatment. And second, we have about 120kg of Simitasertib in storage in the US, which would be convenient in terms of delivery to the NIH,” he said.
Given that Silmitasertib, unlike other potential new drugs under testing for COVID-19, such as remdesivir, does not directly attack the coronavirus or reduce lung damage, it is more likely to be used as a adjuvant drug, Soong said.
However, whether it would be effective and how it would be used with other medication would be determined by the NIH, Soong said.
Silmitasertib marks the only CK2 inhibitor present in clinical trials, he said.
The drug is undergoing a few human tests, including a Phase II trial for bile duct cancer in Taiwan, the US and South Korea, a Phase II clinical trial for medulloblastoma, sponsored by the National Institute of Health-Cancer Therapy Evaluation Program and the Pediatric Brain Tumor Consortium, and a Phase I study for advanced basal cell carcinoma, it said.
Anna Bhobho, a 31-year-old housewife from rural Zimbabwe, was once a silent observer in her home, excluded from financial and family decisionmaking in the deeply patriarchal society. Today, she is a driver of change in her village, thanks to an electric tricycle she owns. In many parts of rural sub-Saharan Africa, women have long been excluded from mainstream economic activities such as operating public transportation. However, three-wheelers powered by green energy are reversing that trend, offering financial opportunities and a newfound sense of importance. “My husband now looks up to me to take care of a large chunk of expenses,
SECTOR LEADER: TSMC can increase capacity by as much as 20 percent or more in the advanced node part of the foundry market by 2030, an analyst said Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) is expected to lead its peers in the advanced 2-nanometer process technology, despite competition from Samsung Electronics Co and Intel Corp, TrendForce Corp analyst Joanne Chiao (喬安) said. TSMC’s sophisticated products and its large production scale are expected to allow the company to continue dominating the global 2-nanometer process market this year, Chiao said. The world’s largest contract chipmaker is scheduled to begin mass production of chips made on the 2-nanometer process in its Hsinchu fab in the second half of this year. It would also hold a ceremony on Monday next week to
TECH CLUSTER: The US company’s new office is in the Shalun Smart Green Energy Science City, a new AI industry base and cybersecurity hub in southern Taiwan US chip designer Advanced Micro Devices Inc (AMD) yesterday launched an office in Tainan’s Gueiren District (歸仁), marking a significant milestone in the development of southern Taiwan’s artificial intelligence (AI) industry, the Tainan City Government said in a statement. AMD Taiwan general manager Vincent Chern (陳民皓) presided over the opening ceremony for the company’s new office at the Shalun Smart Green Energy Science City (沙崙智慧綠能科學城), a new AI industry base and cybersecurity hub in southern Taiwan. Facilities in the new office include an information processing center, and a research and development (R&D) center, the Tainan Economic Development Bureau said. The Ministry
ADVERSARIES: The new list includes 11 entities in China and one in Taiwan, which is a local branch of Chinese cloud computing firm Inspur Group The US added dozens of entities to a trade blacklist on Tuesday, the US Department of Commerce said, in part to disrupt Beijing’s artificial intelligence (AI) and advanced computing capabilities. The action affects 80 entities from countries including China, the United Arab Emirates and Iran, with the commerce department citing their “activities contrary to US national security and foreign policy.” Those added to the “entity list” are restricted from obtaining US items and technologies without government authorization. “We will not allow adversaries to exploit American technology to bolster their own militaries and threaten American lives,” US Secretary of Commerce Howard Lutnick said. The entities